Butterfly Network Q3 2026 earnings

BFLY · 2026-10-29 06:33 BMO ET · 8-K on SEC · 10-Q on SEC

Record quarterly revenue and highest gross margin in company history, with management raising full-year guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$32.6 million+52%—Ex. 99.1, income statement
EPS (GAAP)$(0.05)+62%—Ex. 99.1, income statement
EPS (adjusted)$(0.01)+75%—Ex. 99.1, income statement
Adj. EBITDA$1.2 million+85%—Ex. 99.1, income statement
Adj. EBITDA margin3.7%+1.8 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
U.S.$27.5 million+71%84%Driven by Embedded partnerships and increased probe sales
International$5.1 million-5%16%Decreased probe sales to global health partners

Margins and costs

  • Gross margin 73.0% (prior 63.9%, change +9.1 pp)
  • Operating expenses $37.4 million (+19% YoY)
  • One-offs in the quarter Inventory write-down of $17.4 million (excluded from adjusted gross margin); Warrant liability fair value change of $207
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge Adds back stock-based compensation ($6.7M), inventory write-downs, warrant liabilities, and other non-cash items

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$122.3 million$124.7 million$150.5 million-2.0 million
Weighted-average shares266.5 million262.1 million252.1 million+4.4 million

Guidance

MetricGuidePrior guideChange
Full Year Revenue$123 million to $126 million$119 million to $123 millionRaised
Full Year Adjusted EBITDA$12 million to $15 million$19 million to $23 millionRaised
Q4 Revenue$31 million to $34 million——
Q4 Adjusted EBITDA$3 million to $6 million——

What drove it

  • Revenue story U.S. revenue grew 71% YoY to $27.5 million; International revenue declined 5% YoY to $5.1 million.
  • EPS story EPS improved from $(0.13) to $(0.05) YoY, driven by higher revenue, improved margins, and lower net loss.
  • One-off check Inventory write-downs and write-offs of inventories and vendor advances of $17.5 million (excluded from adjusted gross margin)

The good

  • Record quarterly revenue of $32.6 million (+52% YoY)
  • Highest gross margin in company history at 73%
  • Adjusted EBITDA loss improved 85% YoY to $1.2 million
  • Raised full-year revenue and adjusted EBITDA guidance

The bad

  • Operating expenses increased 19% YoY to $37.4 million
  • International revenue decreased 5% YoY

The ugly

  • none

Open questions

  • The specific dollar amount of the Q4 revenue and adjusted EBITDA guidance range
  • The specific dollar amount of the Q4 adjusted EBITDA loss range
Full release

Earnings: BFLY — filed 2026-10-29

Butterfly Network, Inc. (BFLY) · Form 8-K, Item 2.02 · Filed · SEC filing

Butterfly Network Reports Third Quarter 2026 Financial Results

Beats High End of Quarterly Revenue and Adjusted EBITDA Guidance

• Delivered quarterly Revenue of $32.6 million, driven in part by Embedded revenue

• Recorded highest gross margin in Company history at 73%

• Management increases Full Year Revenue and Adjusted EBITDA Guidance

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Our third quarter results came in ahead of guidance on both revenue and adjusted EBITDA, and we posted the highest gross margin in Butterfly’s history. We saw strength across our business. The enterprise pipeline is turning into signed deals, and achieving FedRAMP authorization puts larger federal opportunities on the table. Home & Community Care has also moved from building the program to executing it, with first revenue expected this November.”

DeVivo continued, “What excites me most is that our progress is compounding as we laid out. Our Ultrasound-on-Chip™ platform is taking Butterfly into entirely new categories, from brain-computer interfaces to physical AI. The first Embedded partner product is now on the market, and we have next-generation technology in motion. Every step forward expands the markets we can serve, and more than a decade of investment in this semiconductor platform is beginning to deliver on the vast potential we have expected.”

Recent Operational and Strategic Highlights:

• Butterfly Embedded™:

Added three BCI partners, including the announcements of Merge Labs and Bridge Neurotech in the third quarter, while Mendaera became the first partner to launch a commercial product built on Butterfly technology on October 1, 2026.

• Compass AI™ and Enterprise Momentum:

Closed five 7-figure and ten 6-figure TCV enterprise deals in the quarter.

• FedRAMP:

Officially achieved FedRAMP authorization as expected, supporting federal and VA pipeline opportunities.

• Medical Education:

Announced the Lighthouse program with VCOM, a multi-year partnership to equip every VCOM student with a Butterfly device and generate insights on POCUS use from medical school into residency.

• Butterfly Garden™:

Signed five new partners, and DeepEcho became the first international and first maternal health partner application to go live on October 23, 2026.

• Home & Community Care:

Entered the implementation phase to launch the first state, with scanning set to begin in November and initial revenue expected in the fourth quarter.

• International Expansion:

Built momentum in Brazil, and added a new distribution partner in Taiwan.

• Innovation Roadmap:

Advanced development of the Apollo chip on schedule; prepared a limited release of wearable research devices for Embedded partners; and continue preparations to launch a next-generation product powered by the P5.1 chip in early 2027.

Three Months Ended September 30, 2026 Financial Results

Revenue:

Total revenue was $32.6 million, representing growth of 52% from $21.5 million in the third quarter of 2025. U.S. revenue was $27.5 million, up 71% from prior year, primarily driven by revenue from our various Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney, as well as increased probe sales volume to our health system, distributor, and eCommerce customers. International revenue decreased 5% year-over-year to $5.1 million, largely resulting from decreased probe sales to our global health partners.

Gross margin:

Gross profit was $23.8 million versus a gross loss of $3.8 million in the prior year period, and adjusted gross profit was $23.8 million versus $13.7 million in the prior year period. Total gross margin, on a GAAP basis, was 73.0% compared to (17.5)% in the prior year period, and adjusted gross margin increased to 73.0% from 63.9% in the prior year period. The $27.6 million increase in GAAP gross margin is due in part to the $17.4 million write-down of excess and obsolete inventory that was recognized during the prior year period, which is excluded from adjusted gross profit and adjusted gross margin. The remainder of the increase in GAAP gross margin, as well as the $10.1 million increase in adjusted gross margin, was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as our increased probe sales volume in the current year.

Operating expenses:

Operating expenses were $37.4 million, up 19% from $31.4 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.6 million, compared to $23.7 million in the third quarter of 2025, largely reflecting increased headcount in the current year from investments we've made in our internal capabilities throughout the past 12 months to support revenue growth as well as our product and software development projects.

Net loss:

Net loss was $12.8 million, compared to $34.0 million in the prior year period.

Adjusted EBITDA:

Adjusted EBITDA loss was $1.2 million, an improvement of 85% compared to $8.1 million in the prior year period.

EPS:

EPS was $(0.05), compared to $(0.13) in the prior year period.

Adjusted EPS:

Adjusted EPS was $(0.01), compared to $(0.04) in the prior year period.

Cash and cash equivalents:

Cash and cash equivalents were $122.3 million as of September 30, 2026.

Guidance

Raised revenue guidance and adjusted EBITDA guidance for the Fiscal Year 2026:

• Revenue of $123 million to $126 million, or approximately 26% to 29% growth

• Adjusted EBITDA loss of $12 million to $15 million... (truncated)dance for the 4th Quarter of 2026:

• Revenue of $31 million to $34 million, or approximately 3% growth year-over-year at the midpoint

• Adjusted EBITDA loss of $3 million to $6 million

Reconciliation of GAAP to Adjusted

Reconciliations of gross profit and gross margin to adjusted gross profit and adjusted gross margin and of net loss and EPS to adjusted net loss, adjusted EBITDA, and adjusted EPS for the three and nine months ended September 30, 2026, and 2025 are provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”

Conference Call

A conference call and webcast to discuss third quarter 2026 financial performance and operational progress is scheduled for 8:00 am ET on October 29, 2026. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at ir.butterflynetwork.com/events-and-presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

US Toll Free: +1 833-461-5787

US East Local: +1 585-542-9983

US West Local: +1 626-884-3620

CA Local: +1 365-657-4084

UK Local: +44 117 389 0104

UK Toll Free: +44 808 196 8935

All dial-in numbers: https://help.events.q4inc.com/eahc/international-dial-in-numbers

Meeting ID: 731 501 731

After the live webcast, the call will be archived on Butterfly’s Investor Relations events page. In addition, a telephone replay of the call will be available until November 5, 2026, by dialing:

Toll Free: +1 833-309-1852

Meeting ID: 731 501 731

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is driving a digital revolution in ultrasound imaging and sensing with its proprietary Ultrasound-on-Chip™ semiconductor technology and software solutions. Butterfly first proved its technology in the point-of-care ultrasound market – commercializing the world's first single-probe, whole-body portable ultrasound device, which is now on its best-selling, third-generation: Butterfly iQ3™. The Company combines its advanced hardware with cloud software and AI, an enterprise workflow solution (Compass AI™) and other offerings to drive adoption of affordable, accessible ultrasound. Butterfly also enables third-party development of imaging AI apps through Butterfly Garden™, its software development kit and AI marketplace.

In addition to its medical imaging products, Butterfly Embedded™ is the Company's Ultrasound-on-Chip™ licensing and co-development business designed to enable a new wave of ultrasound-enabled technologies across non-competitive healthcare markets and beyond. Through Butterfly Embedded™, partners can build and scale novel ultrasound applications powered by Butterfly's proprietary semiconductor chip and software platform.

Butterfly's innovations have been recognized by Prix Galien USA, Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. To learn more, visit: www.butterflynetwork.com

Non-GAAP Financial Measures

In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted net loss, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.

The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted net loss, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.... (truncated)ances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

Forward Looking Statements

Financial statements

Income Statement

Three months ended September 30, — (Unaudited)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Revenue:
Product15,62714,55646,00145,341
Software and other services16,9716,93345,74020,755
Total revenue32,59821,48991,74166,096
Cost of revenue:
Product6,83423,55220,55836,047
Software and other services1,9621,6945,8055,536
Total cost of revenue8,79625,24626,36341,583
Gross profit (loss)23,802-3,75765,37824,513
Operating expenses:
Research and development10,1718,70330,25126,942
Sales and marketing11,60410,62634,48833,805
General and administrative11,5619,28933,73428,018
Other4,0452,7598,0185,451
Total operating expenses37,38131,377106,49194,216
Loss from operations-13,579-35,134-41,113-69,703
Interest income1,0691,4433,3344,598
Interest expense-284-385-845-1,100
Change in fair value of warrant liabilities2074131,652
Other income (expense), net-13-86-1832,824
Loss before provision for income taxes-12,807-33,955-38,394-61,729
Provision for income taxes1643
Net loss and comprehensive loss-12,807-33,971-38,394-61,772
Net loss per common share attributable to Class A and B common stockholders, basic and diluted-0.05-0.13-0.15-0.25
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted266,497,535252,087,541261,741,489245,197,834

Income Statement

Three months ended September 30, — (Unaudited)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Revenue32,59821,48991,74166,096
Cost of revenue8,79625,24626,36341,583
Gross profit (loss)23,802-3,75765,37824,513
Gross margin73-17.571.337.1
Add:
Write-downs and write-offs of inventories and vendor advances17,48617,552
Adjusted gross profit23,80213,72965,37842,065
Adjusted gross margin7363.971.363.6
Depreciation and amortization6498642,1183,405
% of revenue242.35.2

Income Statement

Included on the condensed consolidated statements of operations and comprehensiv — (Unaudited)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Net loss-12,807-33,971-38,394-61,772
Stock-based compensation6,7324,92519,31217,074
Write-downs and write-offs of inventories and vendor advances17,48617,552
Change in fair value of warrant liabilities-207-413-1,652
Other4,0452,7598,0185,451
Other expense (income), net1386183-2,824
Adjusted net loss-2,017-8,922-11,294-26,171
Interest income-1,069-1,443-3,334-4,598
Interest expense2843858451,100
Provision for income taxes1643
Depreciation and amortization1,6151,8855,0866,327
Adjusted EBITDA-1,187-8,079-8,697-23,299
EPS-0.05-0.13-0.15-0.25
Adjusted EPS-0.01-0.04-0.04-0.11
Weighted average shares used to compute EPS and adjusted EPS266,497,535252,087,541261,741,489245,197,834

Balance Sheet

(Unaudited)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents122,301150,489
Accounts receivable, net of allowance for credit losses of $2,015 and $1,389 at September 30, 2026 and December 31, 2025, respectively37,37826,744
Inventories59,58461,389
Current portion of vendor advances2,9222,063
Prepaid expenses and other current assets21,4848,418
Total current assets243,669249,103
Property and equipment, net15,85116,587
Intangible assets, net6,4667,516
Non-current portion of vendor advances4,7985,008
Operating lease assets11,36612,652
Other non-current assets5,8255,667
Total assets287,975296,533
Current liabilities:
Accounts payable5,6575,442
Deferred revenue, current15,92626,909
Accrued purchase commitments, current131
Warrant liabilities, current413
Accrued expenses and other current liabilities46,40432,222
Total current liabilities67,98765,117
Deferred revenue, non-current11,1339,391
Operating lease liabilities15,54617,721
Other non-current liabilities8,8648,325
Total liabilities103,530100,554
Stockholders’ equity:
Class A common stock $0.0001 par value; 600,000,000 shares authorized at September 30, 2026 and December 31, 2025; 245,905,451 and 227,318,426 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively2523

Cash Flow

Nine months ended September 30, — (Unaudited)

Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Cash flows from operating activities:
Net loss-38,394-61,772
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization, and impairments5,0866,327
Non-cash interest expense8441,099
Write-down of inventories7,931
Write-down of vendor advances9,621
Stock-based compensation expense19,31217,074
Change in fair value of warrant liabilities-413-1,652
Other1,375346
Changes in operating assets and liabilities:
Accounts receivable-11,999-3,972
Inventories1,805626
Prepaid expenses and other assets-13,209-1,114
Vendor advances-6493,208
Accounts payable154-943
Deferred revenue-9,241832
Accrued purchase commitments-131
Change in operating lease assets and liabilities-698-633
Accrued expenses and other liabilities13,7291,291
Net cash used in operating activities-32,429-21,731
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets, including capitalized software-3,069-2,265
Net cash used in investing activities-3,069-2,265
Cash flows from financing activities:
Proceeds from exercise of stock options6,084274
Proceeds from employee stock purchase plan1,233949
Net proceeds from share offering81,006
Payments to tax authorities for restricted stock units withheld-7-2,775
Net cash provided by financing activities7,31079,454
Net increase (decrease) in cash, cash equivalents, and restricted cash-28,18855,458
Cash, cash equivalents, and restricted cash, beginning of period154,50492,790
Cash, cash equivalents, and restricted cash, end of period126,316148,248

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results and guidance, including revenue and adjusted EBITDA expectations for the fourth quarter and full year 2026, revenue growth, future performance of our ultrasound business and Embedded opportunities (inclusive of co-development, revenue share/commercialization revenue, chip purchases, and/or chip licensing opportunities through the Embedded program); the timing, scope, and revenue potential of our Butterfly Home and Community Care business, including expectations regarding the commercial launch of our first state program and the timing of initial revenue; expectations regarding the achievement of FedRAMP certification and the expansion of sales to government agencies, including the U.S. Department of Veterans Affairs; the expansion of our Compass AI enterprise software pipeline and related revenue opportunities; expectations regarding international market expansion, including opportunities in Brazil and Taiwan; development and commercialization of products and services, and the size and potential growth of current or future markets for our products and services, including the launches of our next-generation probe, P5 chip, Apollo chip, and fourth-generation technology; the potential for our semiconductor platform to enable new markets through Butterfly Embedded partnerships; expectations regarding the growth of our medical education partnerships and their impact on long-term adoption; and the growth of our Butterfly Garden™ partner ecosystem and AI marketplace. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, as applicable, and any related restrictions and limitations on the use of any authorized product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; the success, cost, and timing of our efforts to out-license our intellectual property to third parties; our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; changes in applicable laws or regulations; the impact of global macroeconomic conditions, including tariffs, geopolitical conflicts, and AI-driven supply chain shortages on our business and operations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to attract and retain customers; our ability to manage our growth effectively; our ability to protect or enforce our intellectual property rights; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contacts:

Investors

John Doherty

Chief Financial Officer, Butterfly investors@butterflynetwork.com

Media

Liz Snyder

Director, PR & Communications, Butterfly media@butterflynetinc.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Butterfly Network earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.